Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Relieved As Mylan Settlement Avoids Investigation

Executive Summary

Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.

Advertisement

Related Content

You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
Mylan Plans Workforce Reduction After M&A And Price Scandal
How Many Pricing Hearings Add Up To Action On Pricing Transparency?
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
EpiPen Medicaid Rebates Could Increase As Mylan, CMS Dispute Heats Up
Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Sanofi Dumps Auvi-Q After Recall
Mylan Finally Nabs Meda In Diversification Play

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel